NASDAQ: BLCMBellicum Pharmaceuticals Inc Stock
$0.32+0.00 (+0%)
Updated Mar 21, 2023
BLCM Price
$0.32
Fair Value Price
$1.25
Market Cap
$2.73M
52 Week Low
$0.27
52 Week High
$2.20
P/E
-1.32x
P/B
0.36x
P/S
24.67x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.50M
Earnings
-$16.25M
Gross Margin
100%
Operating Margin
-1,083%
Profit Margin
-1,083%
Debt to Equity
0.77
Operating Cash Flow
-$25M
Beta
1.03
Next Earnings
Mar 22, 2023
Ex-Dividend
N/A
Next Dividend
N/A
BLCM Overview
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BLCM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BLCM ($0.32) is undervalued by 74.63% relative to our estimate of its Fair Value price of $1.25 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BLCM ($0.32) is significantly undervalued by 74.63% relative to our estimate of its Fair Value price of $1.25 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BLCM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BLCM due diligence checks available for Premium users.
Be the first to know about important BLCM news, forecast changes, insider trades & much more!
BLCM News
Valuation
BLCM fair value
Fair Value of BLCM stock based on Discounted Cash Flow (DCF)
Price
$0.32
Fair Value
$1.25
Undervalued by
74.39%
BLCM ($0.32) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BLCM ($0.32) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BLCM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BLCM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.32x
Industry
16.62x
Market
22.45x
BLCM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.36x
Industry
4.85x
BLCM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BLCM's financial health
Profit margin
Revenue
$1.0M
Net Income
-$7.2M
Profit Margin
-721.3%
BLCM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BLCM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$31.3M
Liabilities
$5.7M
Debt to equity
0.77
BLCM's short-term assets ($31.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BLCM's short-term assets ($31.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BLCM's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BLCM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.9M
Investing
$0.0
Financing
$0.0
BLCM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BLCM vs Biotech Stocks
Bellicum Pharmaceuticals Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.